What is the milliequivalent (mEq) content of K-Dur (potassium chloride) 1.5 mg in a patient with heart failure and potential impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

K-Dur 1.5 mg Conversion to mEq

There appears to be an error in the stated dose, as K-Dur (potassium chloride extended-release) is not manufactured in a 1.5 mg strength. K-Dur is available as 10 mEq (750 mg KCl) and 20 mEq (1500 mg KCl) tablets 1.

Likely Intended Dose Conversions

If the intended dose is 1.5 grams (1500 mg):

  • 1500 mg of potassium chloride = 20 mEq of potassium 1
  • This corresponds to one K-Dur 20 mEq tablet 1

If the intended dose is 750 mg:

  • 750 mg of potassium chloride = 10 mEq of potassium 1
  • This corresponds to one K-Dur 10 mEq tablet 1

Critical Considerations for Heart Failure Patients with Renal Impairment

Target Potassium Range

  • Maintain serum potassium between 4.0-5.0 mEq/L in heart failure patients, as both hypokalemia and hyperkalemia increase mortality risk with a U-shaped correlation 2, 3
  • High-normal potassium levels (5.0-5.5 mEq/L) are associated with improved survival in heart failure patients 3

Dosing Recommendations

  • For prevention of hypokalemia: 20 mEq per day 1
  • For treatment of potassium depletion: 40-100 mEq per day, divided so no more than 20 mEq is given in a single dose 1
  • Each dose should be taken with meals and a full glass of water to minimize gastric irritation 1

Monitoring in Renal Impairment

  • Check potassium and renal function within 2-3 days and again at 7 days after initiation, then monthly for 3 months, then every 3 months thereafter 2
  • More frequent monitoring is essential in patients with renal impairment, heart failure, or concurrent use of RAAS inhibitors 2

Special Cautions

  • Avoid potassium supplementation if patient is on ACE inhibitors or ARBs combined with aldosterone antagonists, as this dramatically increases hyperkalemia risk 4, 2
  • Potassium-sparing diuretics (spironolactone, amiloride, triamterene) are more effective than oral supplements for persistent diuretic-induced hypokalemia and provide more stable levels 2, 5, 6
  • If potassium rises above 5.5 mEq/L, halve the dose; if >6.0 mEq/L, stop immediately 4

Common Pitfall

Never supplement potassium without first checking and correcting magnesium levels, as hypomagnesemia is the most common cause of refractory hypokalemia 2, 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.